Key result
Higher baseline plasma concentrations of ANGPT2 were associated with an increased risk of progression to ESKD or a 40% decline in eGFR.
Why the study?
Prognostic biomarkers reflective of underlying molecular mechanisms are critically needed for effective management of diabetic kidney disease.
Does plasma ANGPT2 level predict the progression to ESKD or 40% eGFR decline in patients with diabetic kidney disease?
Cohort (n=336)
Yes
Does plasma ANGPT2 level predict the progression to ESKD or 40% eGFR decline in patients with diabetic kidney disease?
Plasma ANGPT2 is a prognostic biomarker for diabetic kidney disease progression that reflects underlying glomerular ANG-TIE signaling activation.
This is the authors' abstract. We don't add key points for this paper.
Diabetes is the leading cause of chronic kidney disease. Prognostic biomarkers reflective of underlying molecular mechanisms are critically needed for effective management of diabetic kidney disease (DKD). In the Clinical Phenotyping and Resource Biobank study, an unbiased, machine learning approach identified a three-marker panel from plasma proteomics which, when added to standard clinical parameters, improved the prediction of outcome of end-stage kidney disease (ESKD) or 40% decline in baseline glomerular filtration rate (GFR) in a discovery DKD group (N=58) and was validated in an independent group (N=68) who also had kidney transcriptomic profiles available. Of the three markers, plasma angiopoietin 2 (ANGPT2) remained significantly associated with composite outcome in 210 Chinese Cohort Study of Chronic Kidney Disease participants with DKD. The glomerular transcriptional Angiopoietin/Tie (ANG-TIE) activation scores, derived from the expression of 154 literature-curated ANG-TIE signaling mediators, positively correlated with plasma ANGPT2 levels and outcome, explained by substantially higher TEK receptor expression in glomeruli and higher ANG-TIE activation scores in endothelial cells in DKD by single cell RNA sequencing. Our work suggests that activation of glomerular ANG-TIE signaling in the kidneys underlies the association of plasma ANGPT2 with disease progression, thereby providing potential targets to prevent DKD progression.
Answers are grounded in this paper and cite their sources.
May refine DKD progression risk stratification; leaves open incremental value and therapeutic targeting of ANG-TIE signaling.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) conducted a cohort in Diabetic kidney disease (n=336). Plasma angiopoietin 2 (ANGPT2) levels vs. Lower ANGPT2 levels was evaluated on End-stage kidney disease (ESKD) or more than 40% reduction from baseline eGFR (HR 2.09, 95% CI 1.40-3.12). Higher baseline plasma concentrations of ANGPT2 were associated with an increased risk of progression to ESKD or a 40% decline in eGFR.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: